Drug rationing in the UK National Health Service: Current status and future prospects

PharmacoEconomics

Volumn 12, Issue 3, 1997, Pages 339-350

  Walley, Tom ^a   Haycox, Alan ^a   Barton, Stuart ^a  

^a UNIVERSITY OF LIVERPOOL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BETA INTERFERON;

DRUG USE; HOSPITAL CARE; NATIONAL HEALTH SERVICE; POLITICS; PRESCRIPTION; PRIMARY MEDICAL CARE; PRIORITY JOURNAL; REVIEW;

EID: 0030952605     PISSN: 11707690     EISSN: None     Source Type: Journal    
DOI: 10.2165/00019053-199712030-00006     Document Type: Review

References (66)

1. Bligh J, Walley T. The UK indicative prescribing scheme. Pharmacoeconomics 1992; 2 (2): 137-52
2. UK Department of Health. Pharmaceutical price regulation scheme. London: HMSO, 1993
3. Sheldon T, Maynard A. Is rationing inevitable? In: Rationing in action. London: BMJ Publishing, 1993: 3-14
4. NHS Executive Letter (94) 74. Improving the effectiveness of the NHS. Leeds: NHS Executive. 1994
5. UK Department of Health. Government response to the first report from the Health committee, Session 1994/5. London: HMSO. 1995
6. Smith R. Rationing health care: moving the debate forward. BMJ 1996; 312: 1553-4
7. Crump BJ, Panton R, Drummond MF, et al. Transferring the costs of expensive treatments from secondary to primary care. BMJ 1995; 310: 509-12
8. Crisp R, Hope T, Ebbs D. The Asbury draft policy on ethical use of resources. BMJ 1996; 312: 1528-31
9. New B, on behalf of the Rationing Agenda group. The rationing agenda in the NHS. BMJ 1996; 312: 1593-601
10. Entwistle A, Watt Bradbury R, Pehl L. Media coverage of the Child B case. BMJ 1996; 312: 1587-91
11. UK Department of Health. Annual report. London: HMSO. 1994
12. House of Commons Health Committee. Priority setting in the NHS: the NHS drugs budget. Vol. I. London: HMSO, 1994
13. Freemantle N, Bloor K. Lessons from international experience in controlling pharmaceutical expenditure I: influencing patients. BMJ 1996; 312: 1469-71
14. Bloor K, Freemantle N. Lessons from international experience in controlling pharmaceutical expenditure II: influencing doctors. BMJ 1996; 312: 1525-7
15. Bloor K, Maynard A, Freemantle N. Lessons from international experience in controlling pharmaceutical expenditure. III: regulating industry. BMJ 1996; 313: 33-5
16. Walley T, Wilson R, Bligh J. Current prescribing in primary care in the UK: effects of the indicative prescribing scheme and GP fundholding. Pharmacoeconomics 1995; 7 (4): 320-31
17. Bateman DN, Campbell M, Donaldson LJ. et al. A prescribing incentive scheme for non-fundholding general practices: an observational study. BMJ 1996; 313: 535-8
18. Maxwell M, Heaney D, Howie JGR, et al. General practice fundholding: observations on prescribing patterns and costs using the defined daily dose method. BMJ 1993; 307: 1190-4
19. Wilson RPH, Buchan I, Walley T. Alterations in prescribing by general practitioner fundholders: an observational study. BMJ 1995; 311: 1347-50
20. Stewart-Brown S, Surender R, Bradlow J, et al. The effects of fundholding in general practice on prescribing habits three years after introduction of the scheme. BMJ 1995; 311: 1543-7
21. Wilson RPH, Walley T. Prescribing costs in general practice fundholding. Lancet 1995; 346: 1710-1
22. Wilson R, Hatcher J, Barton S, et al. Fundholders' prescribing savings in one region 1991 to 1994. Health Policy. In press
23. Keeley D. Prescribing costs:fundholders had a head start. BMJ 1994; 308: 206-7
24. Wilson R, Walley T, Effects of fundholding on prescribing habits [letter]. BMJ 1996; 312: 848
25. Dowell JS, Snadden D, Dunbar JA. Changing to generic formulary : how one fundholding practice reduced prescribing costs. BMJ 1995; 310: 505-8
26. Torgerson D, Maynard A. Prescribing practice may have been inefficient (letter]. BMJ 1995; 311: 128
27. Dillner L. GP fundholder reported to the GMC (news item]. BMJ 1996; 312: 334
28. Freemantle N, Henry D, Maynard A. et al. Promoting cost effective prescribing. BMJ 1995; 310: 955-6
29. Walley T, Edwards RT. Health economics in primary care in the UK: containment of drug costs. Pharmacoeconomics 1993; 3 (2): 100-6
30. Walley T, Barton S, Cooke J, et al. Economic evaluations of drug therapy: attitudes of primary care prescribing advisers in the UK. Health Policy. In press
31. Two per cent deterred by prescription charges [news item]. Pharm J 1996; 257: 398
32. Ferner R. Dispensing with prescriptions |editorial|. BMJ 1994; 308: 1316
33. Blenkinsopp A, Bradley C. Over the counter drugs: patients, society and the increase in self medication. BMJ 1996; 312: 629-32
34. Heath I. The creeping privatisation of NHS prescribing. BMJ 1994; 309: 623-4
35. Joshi M, Williams A, Petrie J. Hospital formularies in 1993: where, why and how? Pharm J 1994; 253: 63-5
36. Drummond M, Cooke J, Walley T. Economic evaluation in health care decision making: evidence from the UK. York: Centre for Health Economics. University of York; 1996. Discussion paper no.: 148
37. Bochner F, Martin ED, Burgess N, et al. How can hospitals ration drugs? Drug rationing in a teaching hospital: a method to assign priorities. BMJ 1994; 308: 901-5
38. Donaldson C. How can hospitals ration drugs? Formulate, don't formularise. BMJ 1994; 308: 905-6
39. Petrie J. How can hospitals ration drugs'? First consider the overall process of care. BMJ 1994; 308: 906-7
40. Chadwick R. How can hospitals ration drugs? Fairness is at issue. BMJ 1994; 308: 907
41. Bochner F, Martin ED, Burgess N, et al. How can hospitals ration drugs? Authors' response. BMJ 1994; 308: 907-8
42. Jones R, Rawlins M. Prescribing at the interface between hospitals and general practitioners. BMJ 1992; 304: 4-5
43. Wilkie P, Sibbald B, Raftery J, et al. Prescribing at the interface between hospitals and general practitioners I: hospital outpatient dispensing policies. BMJ 1992; 304: 29-31
44. Sibbald B, Wilkie P, Raftery J. et al. Prescribing al the interface between hospitals and general practitioners II: impact of hospital outpatient dispensing policies on general practitioners and hospital consultants. BMJ 1992; 304: 31-4
45. Audit Commission. A prescription for improvement: towards more rational prescribing in general practice. London: HMSO. 1994
46. NHS Executive Letter (94)72. Purchasing and prescribing. Leeds: NHS Executive. 1994
47. Cantrill J. Interface prescribing. A regional meeting of the UK Drug Utilisation Research Group: 1996 May 20: Liverpool
48. Walley T, Barton S. A purchaser perspective of managing new drugs: beta interferon as a case study. BMJ 1995; 311: 796-9
49. NHS Executive Letter (95)97. New drugs for multiple sclerosis. Leeds: NHS Executive, 1995
50. Bonn D. UK interferon-β-1b trial for treatment of multiple sclerosis shelved. Lancet 1996; 348: 538
51. Cardy P. Equity in prescribing. A Fabian Society Meeting: 1997 Feb 28; London
52. UK court to decide on MS funding. Scrip Mag 1997; 2224: 4
53. Dyer C. Legal challenge to rationing of haemophilia treatment is lost. BMJ 1997; 314: 695
54. Smith C. Managing prescribing: a Labour view. A Fabian Society Meeting: 1997 Feb 28; London
55. Leufkens H, Haaijer-Ruskamp F, Bakker A, et al. Scenario analysis of the future of medicines. BMJ 1994; 309: 1137-40
56. Walley T. A UK national prescribing list? Pharmacoeconomics 1995; 7 (6): 471-4
57. Drummond M, Jefferson T. Guidelines for authors and peer reviewers of economic submissions to the BMJ. BMJ 1996; 313: 275-83
58. Walley T, Edwards RT. Is there a need for an independent centre for pharmacoeconomics in the UK? Pharmacoeconomics 1994; 5 (2): 93-100
59. Mays N. The future of locality commissioning: making it universal raises some difficulties. BMJ 1997; 314: 1212-3
60. Griffin J, editor. The future of primary care. London: Office of Health Economics, 1996
61. The computer will see you now [editorial]. Lancet 1996; 347: 1127
62. Sykes R. Innovation in the pharmaceutical industry. BMJ 1994: 309: 422-3
63. Burns H. Disease management and the pharmaceutical industry: carve out or carve up? Lancet 1996; 347: 1021-3
64. Walley T, Barton S. Disease management. Lancet 1996; 347: 1768-9
65. NHS Executive Letter (94)94. Commercial approaches to the NHS regarding disease management packages. Leeds: NHS Executive, 1994
66. Dean M. New Labour, new healthy Britain? Lancet 1997; 349: 1457